My ePortfolio Register   

The METRIC trial of trametinib, five years on

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 766

Prof Dirk Schadendorf - Essen University Hospital, Essen, Germany

Prof Schadendorf speaks with ecancer at ESMO 2017 about the METRIC trial in melanoma, which initially showed a survival benefit for trametinib.

He reports that, with 5 years of safety and survival data now available, the initial benefits have not translated to a long term survival benefit.

Prof Schadendorf discusses how a changing landscape of targeted and combination therapies has now opened treatment options and dramatically extended patients life expectancy, so while trametinib monotherapy may not retain its initial benefits, it has been an essential stepping stone to the latest generation of melanoma treatments.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence